It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Esophageal cancer is an aggressive malignant tumor. Statistics show that esophageal cancer has claimed the lives of approximately 300,000 people worldwide. Many patients are diagnosed as stage 3 or 4 when they visit a doctor; however, the prognosis may not be accurate because the disease’s early signs are not always evident. The gene ADORA2B may be important in the diagnosis and prognosis of esophageal cancer, as adenosine (ADO) is implicated in the proliferation and spread of many malignancies. Through the use of bioinformatics analysis, this study sought to discover and validate particular genes and putative pathways linked to the course and prognosis of esophageal cancer. Utilizing integrated transcriptomics and single-cell proteomics, the involvement of immune cells in the tumor microenvironment was examined, while bioinformatics was used to investigate the expression, function, and survival data of ADORA2B. Western blot (WB) and qRT-PCR were then used to determine the expression level of ADORA2B in the postoperative tissues of patients with esophageal cancer. Tests using Transwell, Edu, and CCK8 were performed to ascertain its capacity for erosion, migration, invasion, and proliferation. Flow cytometry was used to quantify apoptosis. The results of this investigation validate ADORA2B as a potential therapeutic target and diagnostic biomarker.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer